<?xml version="1.0" encoding="UTF-8"?>
<p id="para410">Fourth, our analysis is limited in scope to 11 priority epidemic infectious diseases. There are many other infectious diseases of epidemic potential that deserve attention according to different priority lists
 <xref rid="bib11" ref-type="bibr">
  <sup>11</sup>
 </xref> and experts' perspectives.
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref> Our estimates of costs draw on contemporaneous information made available on vaccine research and development pipelines for more than just the 11 epidemic infectious diseases, and provide an overall price tag for bringing vaccines against the 11 epidemic infectious diseases successfully through to phase 2. Further pipeline data collection work would be needed to increase the number of diseases included in the cost analysis.
</p>
